CH
Charles Homcy
OtherActivePartner at Third Rock Ventures
58
Investments
0
Exits
—
AUM
0.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Charles Homcy.
Investment Thesis & Strategy
Third Rock Ventures invests in various stages of biotech and pharmaceutical companies, focusing on those with innovative technologies and the potential to address significant unmet medical needs.
Portfolio Companies
Selected investments from their portfolio of 58 companies
S
SAGE Therapeutics
Biotech · Series B, 0
I
Inc.
Other · Seed, 0
M
MyoKardia
Biotech · Series B, 0
T
Thrive Earlier Detection
Biotech · Series B, 0
C
Celsius Therapeutics
Biotech · Series B, 0
I
Igenica
Biotech · Series A, 0
C
Cedilla Therapeutics
Biotech · Series A, 0
F
Faze Medicines
Biotech · Series A, 0
A
Ambys Medicines
Biotech · Series A, 0
G
Global Blood Therapeutics
Biotech · Series B, 0
K
Kala Pharmaceuticals
Biotech · Series B, 0
R
Rhythm Pharmaceuticals
Biotech · Series B, 0
Frequently Asked Questions
Charles Homcy focuses on Seed stage investments.
Related Investors
Bill Coughran
San Francisco, United States · 104 deals
Dave Lambert
San Francisco, United States · 101 deals
Arun Mathew
San Francisco, United States · 99 deals
Ash Rust
San Francisco, United States · 96 deals
Alex Tran
San Francisco, United States · 95 deals
Randy Williams
San Francisco, United States · 95 deals